AcuityMD has raised $80 Million in new Series C Funding

May 26, 2026 Craig Etkin

According to filings with the U.S. Securities and Exchange Commission, AcuityMD is raised $80 Million in new Series C funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About AcuityMD
AcuityMD is the AI platform for MedTech trusted by over 400 MedTech companies including 16 of the top 20. Commercial teams use AcuityMD to identify target markets, surface top opportunities, and grow their business. By combining real-world healthcare data with AI-powered insights, AcuityMD enables companies from pre-commercial to enterprise to understand where and how to sell faster to accelerate the adoption of medical technology. AcuityMD was named to Forbes 2025 Next Billion-Dollar Startups list an elite group of 25 venture-backed U.S. companies identified as most likely to reach a $1 billion valuation.

To learn more, visit https://www.acuitymd.com/
Linkedin Page: https://www.linkedin.com/company/acuitymd/

Contact:
Mike Monovoukas, Chief Executive Officer
https://www.linkedin.com/in/michael-monovoukas-0786a52b/